These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19022153)

  • 1. United States resistance surveillance results for linezolid (LEADER Program for 2007).
    Jones RN; Ross JE; Castanheira M; Mendes RE
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):416-26. PubMed ID: 19022153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linezolid surveillance program results for 2008 (LEADER Program for 2008).
    Farrell DJ; Mendes RE; Ross JE; Jones RN
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):392-403. PubMed ID: 19913682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).
    Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2012 Sep; 74(1):54-61. PubMed ID: 22704791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.
    Jones RN; Kohno S; Ono Y; Ross JE; Yanagihara K
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):191-201. PubMed ID: 19500528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
    Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
    Jones RN; Ross JE; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
    Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
    Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
    Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.
    Draghi DC; Sheehan DJ; Hogan P; Sahm DF
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5024-32. PubMed ID: 16304168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.
    Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3684-90. PubMed ID: 21670176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
    Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
    J Chemother; 2012 Dec; 24(6):328-37. PubMed ID: 23174097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.
    Biedenbach DJ; Farrell DJ; Mendes RE; Ross JE; Jones RN
    Diagn Microbiol Infect Dis; 2010 Dec; 68(4):459-67. PubMed ID: 21094428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.
    Flamm RK; Mendes RE; Hogan PA; Ross JE; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):283-9. PubMed ID: 25633420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
    Flamm RK; Mendes RE; Hogan PA; Streit JM; Ross JE; Jones RN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2273-80. PubMed ID: 26833165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of linezolid resistance in Germany, 2001-2002.
    Brauers J; Kresken M; Hafner D; Shah PM;
    Clin Microbiol Infect; 2005 Jan; 11(1):39-46. PubMed ID: 15649302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates.
    Mendes RE; Jones RN; Deshpande LM; Ross JE; Sader HS
    Microb Drug Resist; 2009 Dec; 15(4):245-9. PubMed ID: 19857129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.